Skip to content

Thiabendazole

Anthelmintic — DERMATOLOGICALS

Also known as: bovizole, equizole, mintesol, mintezol, minzolum, omnizole, thiabendazol, thiabendole, thiabenzole, thibendole, thibenzol, thibenzole

OfmFDA approvedATC D01AC06ATC P02CA02

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Thiabendazole is an ofm drug in the Anthelmintic class catalogued in DrugCentral. It was first approved by the FDA in 1967. DrugCentral lists 10 molecular targets, including HDAC6, map and CYP1A2. Recorded indications include Ancylostoma Duodenale Infection, Ascariasis, Cutaneous larva migrans and Enterobiasis.

  • Approval status: ofm (first approved 1967 by the FDA).
  • Drug class: Anthelmintic.
  • Molecular targets: HDAC6, map, CYP1A2 and METAP1 (10 listed in DrugCentral).
  • Indications: Ancylostoma Duodenale Infection, Ascariasis, Cutaneous larva migrans, Enterobiasis and Infection by larvae of Trichinella spiralis and others.
  • ATC code: D01AC06 (Imidazole and triazole derivatives).
  • Molecular formula: C10H7N3S; molecular weight 201.25 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (10)

  • Ancylostoma Duodenale Infection
  • Ascariasis
  • Cutaneous larva migrans
  • Enterobiasis
  • Infection by larvae of Trichinella spiralis
  • Infection by Strongyloides
  • Infection by Uncinaria
  • Infection due to Toxocara
  • Necator Americanus Infection
  • Trichuriasis

Off-label uses (4)

  • Capillaria infection
  • Infection by Baylisascaris
  • Infection by Dracunculus medinensis
  • Trichostrongyliasis

Contraindications (3)

  • Hepatic failure
  • Kidney disease
  • Liver function tests abnormal

Mechanism & targets

Established pharmacologic classAnthelmintic

Molecular targets (10)

TargetGeneActionActivity
Histone deacetylase 6HDAC6unknownIC50 6.44
Methionine aminopeptidasemapunknownIC50 6.33
Cytochrome P450 1A2CYP1A2unknownIC50 6.10
Methionine aminopeptidase 1METAP1unknownEC50 5.47
Reverse transcriptase/RNaseHpolunknownIC50 4.84
Methionine aminopeptidase 2METAP2unknownIC50 4.35
Peptidyl-prolyl cis-trans isomerase FKBP1AFKBP1AunknownKd 4.22
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrialsdha-1unknown—
Tubulin—inhibitor—
Tubulin—inhibitor—

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1967-04-07FDA——

ATC classification

ATC codeTherapeutic hierarchy
D01AC06DERMATOLOGICALS › ANTIFUNGALS FOR DERMATOLOGICAL USE › ANTIFUNGALS FOR TOPICAL USE › Imidazole and triazole derivatives
P02CA02ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTHELMINTICS › ANTINEMATODAL AGENTS › Benzimidazole derivatives

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Thiabendazole is on its molecule page.

Molecular formulaC10H7N3S
Molecular weight201.25 g/mol
CAS number148-79-8
InChIKeyWJCNZQLZVWNLKY-UHFFFAOYSA-N
PubChem CID5430
N1C2=C(C=CC=C2)N=C1C1=CSC=N1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Thiabendazole used for?

DrugCentral lists the following indications for Thiabendazole: Ancylostoma Duodenale Infection, Ascariasis, Cutaneous larva migrans, Enterobiasis, Infection by larvae of Trichinella spiralis, Infection by Strongyloides, Infection by Uncinaria and Infection due to Toxocara and others.

How does Thiabendazole work?

Its molecular targets in DrugCentral include HDAC6, map, CYP1A2 and METAP1.

When was Thiabendazole first approved?

Thiabendazole was first approved by the FDA in 1967.

What drug class does Thiabendazole belong to?

Thiabendazole is in the Anthelmintic class.

What is the chemical formula of Thiabendazole?

Thiabendazole has the molecular formula C10H7N3S and a molecular weight of 201.25 g/mol.

Browse: all drugs starting with T · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFM
First approval1967-04-07
AgencyFDA
Targets10
Indications10
FormulaC10H7N3S
DrugCentral ID2621
Interactive profile